{"nctId":"NCT03751098","briefTitle":"Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation","startDateStruct":{"date":"2018-12-01","type":"ACTUAL"},"conditions":["Mydriasis"],"count":76,"armGroups":[{"label":"1-TR/PE, 2-Placebo, 3-Placebo","type":"OTHER","interventionNames":["Drug: Tropicamide/Phenylephrine ophthalmic solution (TR/PE)","Drug: Placebo"]},{"label":"1-Placebo, 2-Placebo, 3-TR/PE","type":"OTHER","interventionNames":["Drug: Tropicamide/Phenylephrine ophthalmic solution (TR/PE)","Drug: Placebo"]}],"interventions":[{"name":"Tropicamide/Phenylephrine ophthalmic solution (TR/PE)","otherNames":["Mydcombi"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ability to provide written consent and return for all study visits\n* Photopic pupil diameter \\<= 3.5 mm in each eye\n\nExclusion Criteria:\n\n* Allergy to phenylephrine hydrochloride, tropicamide, or benzalkonium chloride\n* History of benign prostatic hyperplasia\n* Use of a benzodiazepine, monoamine oxidase inhibitor, tricyclic antidepressant, anticonvulsant, or cholinergic drug\n* History of closed-angle glaucoma\n* Anatomically narrow anterior chamber angles\n* Ocular surgery or laser treatment of any kind\n* History of chronic or acute uveitis\n* History of traumatic iritis or hyphema\n* History of traumatic mydriasis or angle recession\n* History of heterochromia\n* Irregularly-shaped pupil secondary to ocular trauma or congenital defect.\n* History of neurogenic pupil disorder\n* History of anterior chamber intraocular lens (IOL) or iris-fixated IOL\n* History of iris surgery, iris atrophy, or iris-cornea apposition/touch\n* Unwilling or unable to discontinue use of contact lenses at treatment visits.\n* Current active eye disease for which topical or systemic ophthalmic medication is necessary, except for dry eye disease managed using artificial tears.\n* Presence of a severe/serious ocular condition, or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment and/or follow-up\n* Pregnancy or lactation","healthyVolunteers":true,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Pupil Diameter From Baseline","description":"Difference in 35-minute pupil diameter vs. baseline measured using pupillometry in highly photopic conditions.\n\nPupil diameter is reported in millimeters. For the change in pupil diameter, larger measurements indicate a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.747","spread":"0.7301"},{"groupId":"OG001","value":"4.779","spread":"0.8032"},{"groupId":"OG002","value":"0.134","spread":"0.4972"},{"groupId":"OG003","value":"0.032","spread":"0.4983"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.597","spread":"0.4784"},{"groupId":"OG001","value":"2.524","spread":"0.4802"},{"groupId":"OG002","value":"2.632","spread":"0.5202"},{"groupId":"OG003","value":"2.559","spread":"0.4666"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.344","spread":"0.7981"},{"groupId":"OG001","value":"7.304","spread":"0.8264"},{"groupId":"OG002","value":"2.766","spread":"0.6598"},{"groupId":"OG003","value":"2.590","spread":"0.5892"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Proportion of Eyes Achieving Pupil Diameter 6.0 mm or Larger After Receipt of Each Medication","description":"The percent of eyes with pupil diameter 6.0 mm or larger as measured using pupillometry in highly photopic conditions. As this is a cross-over study, each of the 69 participants received each medication. Data is reported separately for the right and left eyes of the 69 participants. A higher percentage indicates a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8","spread":null},{"groupId":"OG001","value":"94.2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Proportion of Eyes Achieving Pupil Diameter 7.0 mm or Larger After Receipt of Each Medication","description":"The percent of eyes with pupil diameter 7.0 mm or larger as measured using pupillometry in highly photopic conditions. As this is a cross-over study, each of the 69 participants received each solution. Data is reported separately for the right and left eyes of the 69 participants. A higher percentage indicates a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":null},{"groupId":"OG001","value":"68.1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":69},"commonTop":["Photophobia","Instillation site pain"]}}}